May. 12 at 2:45 PM
$CRBP Market cap 200 mil, cash 140 mil and cash runway until 2028. Meaning the current value of the pipeline is 60 mil while both drugs have an inflection point in few months. First up is ASCO and P3 initiation soon thereafter for CRB-701 (other companies having somewhat similar efficacy results for their drugs in HNSCC are valued between 500-1500 mil). Then becomes the main event in the late summer when the company either goes through the roof due to new blockbuster obesity drug being born or concentrates in their cancer drug pipeline that should be worth the mentioned 500-1500 mil just by itself. It's hard to understand why more people are not buying in panic mode RIGHT NOW.
